Cargando…
Current and Emerging Pharmacotherapies for the Treatment of Relapsed Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a very aggressive cancer with poor outcome if left untreated, but it is also one of the most chemotherapy responsive cancers. Overall it has a very poor prognosis especially if it is chemotherapy resistant to first line treatment. Second line chemotherapy has not bee...
Autores principales: | Nair, Binu S., Bhanderi, Vipul, Jafri, Syed H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153118/ https://www.ncbi.nlm.nih.gov/pubmed/21836818 http://dx.doi.org/10.4137/CMO.S5964 |
Ejemplares similares
-
Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
por: Furtado, Michelle, et al.
Publicado: (2012) -
Pharmacotherapies for COPD
por: Ejiofor, Stan, et al.
Publicado: (2013) -
Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012) -
Choosing pharmacotherapy for ILD in patients with connective tissue disease
por: Wu, Zhe, et al.
Publicado: (2021) -
Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
por: Yalin, Nefize, et al.
Publicado: (2020)